Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06671379 | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 498 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04379635 | Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 453 | BeiGeneINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06726265 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | active not recruiting | Phase 3 | 756 | Immutep S.A.S.INDUSTRY | 27 | Mar 18, 2026 | clinicaltrials |
| NCT07464327 | A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | not yet recruiting | Phase 3 | 450 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Mar 11, 2026 | clinicaltrials |
| NCT05499390 | AK112 in Advanced Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 398 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432) | active not recruiting | Phase 3 | 152 | Eli Lilly and CompanyINDUSTRY | 32 | Mar 4, 2026 | clinicaltrials |
| NCT05184712 | Phase 3 Clinical Study of AK112 for NSCLC Patients | active not recruiting | Phase 3 | 322 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07442565 | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ(SYNSTAR03) | not yet recruiting | Phase 3 | 506 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 4, 2026 | clinicaltrials |
| NCT07174908 | A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | recruiting | Phase 3 | 400 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03774732 | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer(NIRVANA-LUNG) | active not recruiting | Phase 3 | 327 | UNICANCEROTHER | 2 | Feb 25, 2026 | clinicaltrials |
| NCT04428905 | Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | active not recruiting | Phase 3 | 403 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER) | active not recruiting | Phase 3 | 453 | Eli Lilly and CompanyINDUSTRY | 21 | Feb 6, 2026 | clinicaltrials |
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 500 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04339218 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma(CRYOMUNE) | recruiting | Phase 3 | 214 | Institut BergoniéOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05502237 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer(STAR-121) | active not recruiting | Phase 3 | 1,021 | Gilead SciencesINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT06984588 | A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 450 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07362459 | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | recruiting | Phase 3 | 246 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)(RELAY) | active not recruiting | Phase 3 | 545 | Eli Lilly and CompanyINDUSTRY | 14 | Jan 16, 2026 | clinicaltrials |
| NCT06908304 | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | recruiting | Phase 3 | 300 | Maia BiotechnologyINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT05609968 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | active not recruiting | Phase 3 | 614 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Dec 24, 2025 | clinicaltrials |
| NCT02201992 | Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | active not recruiting | Phase 3 | 166 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 19, 2025 | clinicaltrials |
| NCT06908993 | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated(COMET) | recruiting | Phase 3 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07182682 | A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery | recruiting | Phase 3 | 360 | Dizal (Jiangsu) Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03052608 | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | active not recruiting | Phase 3 | 296 | PfizerINDUSTRY | 23 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07242274 | Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC | not yet recruiting | Phase 3 | 472 | JemincareINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04980716 | Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 524 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07170995 | Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 3 | 460 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07178795 | A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC | recruiting | Phase 3 | 440 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer(LIBRETTO-431) | active not recruiting | Phase 3 | 261 | Eli Lilly and CompanyINDUSTRY | 26 | Oct 21, 2025 | clinicaltrials |
| NCT04695925 | Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations(TOP) | active not recruiting | Phase 3 | 294 | Li Zhang, MDOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT02767804 | eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | active not recruiting | Phase 3 | 290 | Xcovery Holdings, Inc.INDUSTRY | 20 | Oct 14, 2025 | clinicaltrials |
| NCT07197853 | Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial(HAMSTER) | not yet recruiting | Phase 3 | 180 | Xin YeOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT05020769 | SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | active not recruiting | Phase 2 / Phase 3 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07154368 | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. | not yet recruiting | Phase 3 | 207 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 19, 2025 | clinicaltrials |
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %(PERSEE) | active not recruiting | Phase 3 | 349 | University Hospital, BrestOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06840782 | First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.(OliGRAIL) | recruiting | Phase 3 | 124 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07169903 | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012) | not yet recruiting | Phase 3 | 587 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05278052 | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC(TARGET-02) | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07162883 | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 122 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07150663 | Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 134 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06505837 | JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） | active not recruiting | Phase 3 | 395 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06417008 | A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,080 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06734702 | Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | recruiting | Phase 3 | 497 | Sun Yat-sen UniversityOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07052669 | Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC | recruiting | Phase 3 | 311 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07076693 | Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） | active not recruiting | Phase 2 / Phase 3 | 97 | Shanghai Chest HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07050043 | Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC(LEDANG) | recruiting | Phase 3 | 123 | Dr Arvindran A/L AlagaOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05943795 | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | active not recruiting | Phase 3 | 589 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05989542 | A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)(KUNPENG-2) | recruiting | Phase 3 | 136 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05116462 | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | active not recruiting | Phase 3 | 506 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 19, 2026source: clinicaltrials